You are here: Industry Insights > COVID-19

News List

Humanigen, Emergent Enter Covid-19 Partnership contractpharma
January 26, 2021
Sign contract development and manufacturing agreement for Phase 3 COVID-19 therapeutic candidate lenzilumab.
Elasmogen identifies potential vaccine candidates to fight Covid-19 pharmaceutical-technology
January 26, 2021
Elasmogen has identified protein-based drugs that can potentially stop Covid-19 infections, through a partnership with the University of Minnesota.
Telemedicine to benefit the most from remote patient monitoring tools: Poll pharmaceutical-technology
January 26, 2021
The COVID-19 pandemic has led to a surge in the use of remote patient monitoring (RPM) tools to monitor patients outside the standard healthcare settings.
How is a vaccine engineered? expresspharma
January 26, 2021
Vaccines are among the most effective means of preventing infectious diseases. Vaccines train our immune system to mount a defence against pathogens by creating antibodies.
Moderna believes its vaccine will protect against new COVID-19 variants expresspharma
January 26, 2021
The company said it found no reduction in the antibody response against the variant found in Britain.
Gavi to make 500,000 doses of Ebola vaccine available for outbreak response europeanpharmaceuticalreview
January 25, 2021
The global stockpile will provide developing countries responding to Ebola outbreaks with doses of the approved single-dose Ebola vaccine, rVSV?G-ZEBOV-GP, live, free of charge.
COVAX announces new agreement, plans for first deliveries worldpharmanews
January 25, 2021
COVAX announced the signing of an advance purchase agreement with Pfizer for up to 40 million doses of the Pfizer-BioNTech vaccine candidate, which has already received WHO emergency use listing.
Gilead's Veklury should be effective against COVID-19 variants pharmatimes
January 25, 2021
Gilead Sciences has released a statement regarding the efficacy of its antiviral treatment Veklury (remdesivir), maintaining confidence in the its continued benefit against new COVID-19 variants.
Jubilant, Wistar Institute to Evaluate Novel PAD4 Inhibitors to Reduce Severity of COVID-19 americanpharmaceuticalreview
January 25, 2021
Jubilant Therapeutics has announced a collaboration with The Wistar Institute to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the ...
FDA Publishes New Guidance on Protecting Participants in Bioequivalence Studies During COVID-19 americanpharmaceuticalreview
January 25, 2021
The U.S Food and Drug Administration (FDA) has published a new guidance for industry, Protecting Participants in Bioequivalence Studies for Abbreviated New Drug Applications During the COVID-19 Public Health Emergency.